Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia
Launched by ALEN GREŠ · Jun 29, 2020
Trial Information
Current as of June 17, 2025
Unknown status
Keywords
ClinConnect Summary
In the first phase of the research, the development of the research protocol and obtaining it will be done of his approval.
The second phase of the research will include patients with schizophrenia disorders based on inclusive and exclusive criteria and a study will be conducted procedure. In the third phase of the research, the obtained results are processed and analyzed.
The content of the dissertation will include an introduction, a goal with hypotheses, methods, results, discussion, conclusions and literature. In the introduction, in addition to current knowledge about schizophrenia a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * age between 18 and 50, informed consent signed, confirmed diagnosis of schizophrenia, taking monotherapy with antipsychotics: aripiprazole, risperidone, paliperidone or olanzapine, unchanged dose maintenance back at least 6 months, remission of psychotic symptoms (PANSS ≤ 70), and that they do not have any of the exclusive criteria:
- Exclusion Criteria:
- • taking benzodiazepines at doses equivalent to ≥ 10 mg diazepam, taking mood stabilizers, antidepressants three months ago, abuse of addictions back three months, suicide attempt back 6 months, suicidal, heteroaggressive, or other similar behavior back 6 months, somatic comorbidities affecting cognitive functions (intellectual disabilities, significant neurological disease or head trauma), pregnancy
About Alen Greš
Alen Greš is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on ethical practices and regulatory compliance, Alen Greš collaborates with leading research institutions and healthcare professionals to conduct robust clinical trials across various therapeutic areas. The organization prioritizes patient safety and data integrity, aiming to contribute valuable insights to the scientific community while fostering trust and transparency in all its endeavors. Through a strategic approach to study design and execution, Alen Greš strives to facilitate the development of effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagreb, , Croatia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials